Princeton Global Asset Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

Princeton Global Asset Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 29,127 shares of the biopharmaceutical company’s stock after purchasing an additional 1,591 shares during the quarter. Princeton Global Asset Management LLC’s holdings in Pfizer were worth $1,032,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PFE. 1 North Wealth Services LLC purchased a new stake in shares of Pfizer during the 3rd quarter valued at approximately $29,000. Salomon & Ludwin LLC increased its position in shares of Pfizer by 362.7% during the 3rd quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 700 shares during the last quarter. Bourgeon Capital Management LLC purchased a new stake in Pfizer in the 3rd quarter valued at about $32,000. B & T Capital Management DBA Alpha Capital Management purchased a new stake in Pfizer in the 3rd quarter valued at about $36,000. Finally, Financial Gravity Wealth Inc. raised its holdings in Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 257 shares during the period. Institutional investors own 70.25% of the company’s stock.

Several research analysts have weighed in on the stock. Morgan Stanley lowered their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 27th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Bank of America began coverage on shares of Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 target price for the company. UBS Group reissued a “neutral” rating and issued a $43.00 target price on shares of Pfizer in a research report on Monday, August 5th. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target on the stock in a research note on Tuesday, October 1st. Nine equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $43.19.

In other news, major shareholder Pfizer Inc acquired 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, with a total value of $900,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.09% of the stock is owned by insiders.

Shares of Pfizer stock traded down $0.24 during trading hours on Tuesday, reaching $38.05. 19,831,631 shares of the company were exchanged, compared to its average volume of 23,212,844. The firm has a market cap of $210.57 billion, a PE ratio of 12.68, a PEG ratio of 3.41 and a beta of 0.66. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.68 and a current ratio of 0.90. Pfizer Inc. has a 1 year low of $33.97 and a 1 year high of $46.47. The stock’s fifty day moving average is $37.44 and its 200 day moving average is $38.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The business had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $12.37 billion. During the same quarter last year, the business posted $0.78 EPS. The business’s quarterly revenue was down 4.6% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.97 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were issued a $0.36 dividend. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.78%. Pfizer’s dividend payout ratio (DPR) is 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: How is the Producer Price Index calculated?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.